Date: 2013-06-11
Type of information: R&D agreement
Compound: small molecule compounds
Company: UCB (Belgium) CRELUX (Germany) 4SC Discovery (Germany)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: * On June 11, 2013, UCB, 4SC and CRELUX have announced that they have started a drug discovery collaboration to identify and validate novel small molecule compounds for the treatment of neurological disorders. Based on their joint idea-to-candidate (i2c) platform, CRELUX and 4SC Discovery will discover and optimize small molecule compounds with the goal to deliver high quality drug candidates to UCB. UCB thus aims to identify novel medicines for treatment of diseases of the central nervous system (CNS) and take them into further preclinical and clinical development.
Under this agreement a virtual screening approach based on 4SC´s proprietary 4Scan method will be performed to identify various inhibitors to the therapeutic target enzyme. Compounds identified as binders will be verified in vitro at CRELUX using their INTRACT assay capabilities. Subsequently, co-crystal structures of verified hits with the target will be solved by CRELUX to enable rational design and guide the further chemical optimization.
The i2c platform operates on a seamlessly integrated suite of technologies including virtual high throughput screening, molecular modelling, X-ray crystallography, in vitro and cell based screening medicinal chemistry and pharmacology. CRELUX and 4SC Discovery are offering integrated drug discovery services to clients from the pharmaceutical and biotechnology industry covering the entire value chain of early-stage pharmaceutical research and drug discovery.
This agreement further extends to an earlier successful collaboration of the three companies.
Financial terms: Financial details of the collaboration were not disclosed.
Latest news:
